Home > Journals > Minerva Gastroenterologica e Dietologica > Past Issues > Minerva Gastroenterologica e Dietologica 2013 March;59(1) > Minerva Gastroenterologica e Dietologica 2013 March;59(1):13-23

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GASTROENTEROLOGICA E DIETOLOGICA

A Journal on Gastroenterology, Nutrition and Dietetics


Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

  CUTTING EDGE GASTROENTEROLOGY


Minerva Gastroenterologica e Dietologica 2013 March;59(1):13-23

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

Management of Barrett’s esophagus

Rahman A. A. 1, Singh R. 1, Sharma P. 2

1 Department of Gastroenterology, Lyell McEwin Hospital and University of Adelaide, Elizabeth Vale, South Australia, Australia; 2 Division of Gastroenterology and Hepatology, Veterans Affairs Medical Center and University of Kansas School of Medicine, Kansas City, MO, USA


PDF  


Both the incidence of esophageal adenocarcinoma (EA) and its precursor, Barrett’s esophagus (BE) is increasing rapidly in the western world. The progression of BE to EA follows the metaplasia-dysplasia-carcinoma sequence which makes BE the focus of intervention before the development of EA. Considerations are given on the feasibility of a screening program for the population at risk, followed by surveillance of patients found to have BE on endoscopy. Potential management options are then stratified based histological findings of various degrees of dysplasia. This begins with watchful waiting or surveillance as in the case of BE with no dysplasia and low-grade dysplasia (LGD). Ablative therapies such as radiofrequency ablation (RFA) can be considered in non-visible high-grade dysplasia (HGD). With visible lesions and intramucosal cancers, Endoscopic Mucosal Resection (EMR) or Endoscopic Submucosal Dissection (ESD) is generally recommended as a treatment and staging technique. Esophagectomy remains the treatment of choice in EA where there is a high risk of metastasis such as those with deeper submucosal invasion, lymph-vascular or neural invasion and those of higher tumour grade.

top of page

Publication History

Cite this article as

Corresponding author e-mail

rajvinder.singh@health.sa.gov.au